Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...
Revenue: US$2.77b (up 12% from 3Q 2023). Net income: US$1.05b (up 1.0% from 3Q 2023). Profit margin: 38% (down from 42% in 3Q 2023). EPS: US$4.05 (up from US$4.01 in 3Q 2023). Revenue exceeded ...
Zacks.com on MSN5d
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating today. Jake Roberge has given his ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback